Mode
Text Size
Log in / Sign up
Phase 2 Completed N=40 Randomized Treatment

HOP-3 Manipulation of the Intratesticular Hormonal Milieu With Exogenous Testosterone

Healthy Males
Source: ClinicalTrials.gov NCT00839319 ↗
Enrolled (actual)
40
Serious AEs
0.0%
Results posted
Nov 2010
Primary outcomePrimary: Serum Testosterone (T) — 0.43; 1.5; 3.7; 8.4 nmol/liter — p=<0.05

Summary

The purpose of this investigational study is to determine how much male hormone, testosterone, is necessary to maintain sperm production in the testis. This knowledge will be used to help in the development of a safe male hormonal contraception.

Outcome Measures

OutcomeResultp-value
PRIMARY
Serum Testosterone (T)
0.43; 1.5; 3.7; 8.4; 16 <0.05 sig
PRIMARY
Serum Luteinizing Hormone (LH)
0.13; 0.28; 0.49; 0.39; 0.14
PRIMARY
Serum Follicle Stimulating Hormone (FSH)
0.41; 0.41; 0.29; 0.28; 0.21
PRIMARY
Intratesticular Testosterone (ITT-T)
77; 136; 319; 987; 73

Eligibility Criteria

Inclusion Criteria

  • Males age 18-50
  • Normal serum testosterone, LH and FSH
  • PSA 32
  • Subjects with a skin condition that might interfere or be exacerbated by testosterone gel use
  • Subject's with alcohol or drug use
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00839319). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search